Funded Tech Companies

Phathom Pharmaceuticals

Researching who provided funding to Phathom Pharmaceuticals? BVF Partners, Greenspring Global Partners and Frazier Healthcare Partners put venture money into this innovative biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

Phathom Pharmaceuticals (Nasdaq: PHAT), launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB).

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

10/24/2019

Financing History

Management Team

Title

Name

Email & Social

Chairman

Tadataka Yamada

        

Chief Executive Officer

David Socks

        

Chief Operating Officer

Azmi Nabulsi

        

Chief Scientific Officer

Roger Ulrich

        

VP - Bus. Development

Aditya Kohli

        

Company Investors

• BVF Partners
• Greenspring Global Partners
• Frazier Healthcare Partners
• Abingworth
• Medicxi Ventures
• RA Capital
• Sahsen Ventures
• Silicon Valley Bank
• Janus Henderson Investors
• Richard King Mellon Foundation

Browse more funded tech companies:

Phasiq | Phaver

Share this article

About Our VC Transaction Database

Our data comes from VentureDeal.com, a leading supplier of venture capital funding data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary